Member Info for rivaldo

Cheers Qd22 - at least the start of the article is visible:

""This is the first in our new series of articles introducing fast growing smaller quoted companies. Our main focus here is on hunting out companies generating strong organic sales growth, ideally with plenty of profits and cash, although we are willing to forgive that if the top line is soaring! First up is a rapidly growing small business which has already impressed since arriving on AIM in 2020. (IHT qualifying)

The roll-out of 5G and the evolving nature of the telecoms market provides a highly supportive environment for this small testing business, which hasn't missed a beat since its IPO on AIM in 2020. If growth can be maintained, which appears likely, the shares look compelling value.

Founded in 2006 and with its headquarters in Linlithgow, Scotland, Calnex Solutions (LON:CLX) designs, produces and markets test and measurement instrumentation and solutions for the global telecommunications sector, enabling its telecom customers to validate the performance of critical infrastructure associated with telecoms networks.

Calnex has an established position in the test and measurement industry,¦...etc"

Excellent presentation on InvestorMeet today. It's ironic that most people are (rightly) expecting great things from 5G and water management, but it's been the Consultancy division which has really taken off over the last couple of years and looks likely to continue thrive.

I feel that MWE are in a great position now, given that not only are they intmately involved in fast-grwoing sectors, but this year onwards their already impressive 19% PBT growth should be further accelerated by the rebound from the pandemic.

Net cash is forecast to be almost $10.5m at the end of this year. MWE's acquisitions to date have worked out extremely well - another one will hopefully be more sizeable and enhance earnings nicely.

Per CORA's RNS this morning, and from Finncap's note on Cora this morning - good to see CAPD directly referenced:

"Sanankoro drill programme starts
Cora has announced the start of its 2021 drilling programme, solely focused on its flagship project,Sanankoro. The programme is designed to (1) upgrade areas of the existing resource to Measured & Indicated in preparation for the feasibility study (2) expand the resource through drill testing some of the known, but as yet undrilled, gold structures.

Drilling will commence in the coming days with an initial 22,000 metres. This will be followed by a further 13,000 metres for a total 35,000 metres of Reverse Circulation and diamond drilling. The drilling will be delivered by Capital Drilling and should be completed in July."

BPat890, thanks for the good wishes - I don't generally post or patrol bb's unless I have something specific to say. So there can be long gaps between my posts!

Good start to the week.....

Good H1 results today given the pandemic - particularly with the cash pile up to £3.9m against the £10.7m m/cap!

The outlook is very good too - "Positive trading patterns have continued into the second half of the year", and "Well placed for a satisfactory result for the year".

With 36% of the m/cap represented by the cash pile, that means CSSG are on track to make an annualised PAT of almost £800,000 against a net EV of only £6.8m.....

Zeus Capital this morning conclude as below that CNIC are "attractively valued" - they've raised their revenue forecast for this year whilst keeping EBITDA the same, and have raised EBITDA forecasts for next year to $45.7m:

"Valuation

CentralNic is attractively valued against both direct and indirect peers. The company trades well below GoDaddy, its closest significant peer, but we are cognisant that it is listed on the highly valued NASDAQ market.

Regardless, CentralNic also appears undervalued against UK managed services peers. CentralNic trades on a PE of 12.5x FY2 compared to a median of 18.6x for this peer group,despite offering significantly higher EPS growth of 26% compared topeergroup median of 6%. The company's EV/ EBITDA FY2 is approximately in line with UK managed services peers while CentralNic offers higher earnings growth. We believe strong earnings performance should lead to multiples expansion while further accretive acquisitions could drive strong earnings growth. We expect these drivers should lead CentralNic shares to outperform over the medium term."

Results are out - revenues are way ahead of expectations at $241.2m against forecast $228m.

And 10.25c adjusted EPS is also way ahead of expectations of 8.9c.

Importantly, this year has begun well with nicely in-line trading. And recurring revenues are at 99% now.....

Of course there are lots of adjustments to get to that adjusted EPS, stripping out amortisation, non-core expenses etc. I'm OK with that to see what the continuing core business is achieving - which shows it's in fine fettle.

Very good results in the face of the pandemic, with PBT up 19%, revenues ahead of expectations - and net cash way ahead of expectations at $9.4m.

Most importantly:

"The first two months of 2021 have started well and we look forward to delivering another year of solid growth."

The $9.4m cash pile is a sizeable part of the £73m m/cap (alongside the $2.7m freehold property). Prospects for all 3 divisions - antennas and 5G, water management and consulting - look very good indeed.

Allenby Capital have raised their fair value/price target to 95p (from 63p).

Their historic adjusted 2.72p EPS is presumably less than forecast 3.39p due to the Antenna and Mottech divisions' COVID-affected results. They see 3.16p EPS this year, so that's a current year P/E of 23.7 after stripping out the roughly 8p per share cash pile.

Given the prospects - and the likelihood of a post-COVID bounce, particularly given the huge vaccination programme success in Israel - that's a reasonable P/E imo, especially in the current market.

Good to see some buys coming in at the full 24p offer price in the last half hour.

If Duroc are now out then things could get very interesting.

Per this Feb 17th press release, Darlington Borough Council "has added EV charging points to power its current fleet of nine electric vehicles that are used by its Building Services Department".

And "The next stage of Darlington Borough Council’s plan is to update its 250-vehicle fleet to EV power", all part of a National Framework Agreement being implemented by Innogy.

What has this to do with RNWH? Well, Clarke Telecom has a ClarkeEV subsidiary, who happen to be Innogy's installation partner - imagine the revenues accruing from this over the next decade or so.......

Https://clarke-ev.com/about/

Https://myessentialfleet.co.uk/innogy-is-enabling-darlington-borough-councils-switch-to-electric-vehicle-power/

"innogy’s highly-skilled installation partner, Clarke EV, delivered all enabling civils works and electrical installs at Darlington Borough Council. This included charging points across its Allington Way and Lingfield Way depots. The innogy eClick and eBox chargers that form part of the new infrastructure can easily be swapped out or changed – a flexible and totally unique feature in the EV marketplace.

“innogy eMobility and Clarke EV delivered a superb job that the team should be really proud of.”
Gary Bennett, Waste & Transport Services Manager, Darlington Borough Council"

"The EV charging point roll out at Darlington Borough Council comes hot on the heels of innogy’s collaboration with Oxford City Council which is striving to reduce the city’s CO2 emissions by 750 tonnes per year by switching its 27-strong refuse vehicle fleet to electric power."

Finncap retain their 11p target price today, and conclude:

"Implications: Byotrol’s principal products pass this test, with claims supporting 24-hour protection against viruses and bacteria in real-life conditions, where surfaces are frequently touched. Therefore, if the new test is adopted by the BSI, other companies will have to pass the test if they are to make long-lasting anti-viral claims; enabling businesses and consumers to use products which are proven to be effective in a variety of public spaces where surfaces are frequently touched.

Procter & Gamble has launched a marketing campaign in the UK for Microban24 (it is the only other EPA-approved product in the US to have a long-lasting claim against bacteria), however, whilst it provides an initial kill against the virus, it does not make the 24-hour claim for viruses.

Byotrol will be able to differentiate its products, building on the increased public awareness of 24-hour efficacy, albeit in the case of Microban24, against bacteria only.

?Valuation.

We reiterate our target price of 11p, which would place the stock on an FY 2021 EV/Sales, EV/EBITDA and P/E of 4.1x, 27xand 33.9x, respectively."

Logistics is the place to be :o))

Good article here on Liberum's initiation of coverage:

"Liberum initiates coverage on Medica at 'buy'
Iain Gilbert
25 Feb, 2021 13:37 25 Feb, 2021 13:37

Analysts at Liberum initiated coverage on teleradiology firm Medica on Thursday at 'buy', pointing to faster earnings per share growth, higher earnings quality and underestimated optionality.

Liberum said Medica's new management team had made "the right investments" to take advantage of surging end-market demand and "incredibly tight supply", a move that the analysts believe will allow it to deliver a 20% organic EPS compound annual growth rate to 2025.

Furthermore, Liberum expects Medica to use its strong balance sheet for EPS accretive mergers and acquisitions that will diversify the business into new services and geographies.

Liberum also acknowledged Medica's addition of new chief executive and chief financial officers over the last two years, highlighting the team's "ambitious plans" to optimise growth in the firm's core markets through recent investments that were now bearing fruit.

"We believe that Medica is set to deliver some of the fastest EPS growth in the UK healthcare services sector whilst M&A provides significant optionality. Yet it trades at a c.45% discount to peers," said Liberum.

"We expect this valuation gap to close over the next 12-18 months with earnings delivery and further M&A. We, therefore, initiate with a BUY rating and a £2.00 TP, implying 71% upside. Medica is now our top pick in UK SMID."

There's a useful transcript of the interview from the other day with the Zeus Capital analyst here:

Https://www.***************************/surface-transforms-analyst-qa-embarking-on-an-exciting-phase-of-investment-and-growth-lonsce/412963862

And a very strong endorsement of SCE's brakes here:

https://www.r8talk.com/threads/the-best-brake-rotors-on-the-planet-period.172826/#post-1584800

https://twitter.com/SureMaintenance/status/1361604464084455425

"We are delighted to announce our commercial gas servicing, maintenance and repair contract win with Rotherham Metropolitan Borough Council, for an initial two year term, with an option to extend. This contract will expand our already successful operations across Yorkshire. (1/2)
9:12 AM · Feb 16, 2021·"

CLX' Twitter feed is quite active. Here's a couple of recent interesting posts...it's a good sign that CLX continue to hire, and confirmation that the partnership with Spirent remains strong:

Https://twitter.com/CalnexSolutions?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

"Calnex Solutions
@CalnexSolutions
·
Feb 18
Calnex is #hiring! We have opportunities available for:

• Product Applications/Support Engineer (Linlithgow)
• Senior Hardware Design Engineer (Linlithgow)
• Hardware Design Engineer (Linlithgow)

For more information and to apply, please click:
https://calnexsol.com/en/careers"

"Calnex Solutions
@CalnexSolutions
·
Feb 17
We have partnered with @Spirent on the new eBook "The Need for Timing and Synchronization in a #5G World" highlighting the synchronization requirements of applications such as O-RAN, Disaggregation and Network Slicing. View it here: https://spirent.com/assets/ebook-the-need-for-timing-and-synchronization-in-a-5g-world
Quote Tweet
Spirent
@Spirent
· Feb 5
How is the #5G #network changing and why is #synchronization so important? Find out here
??
https://okt.to/gv6Hjn"

Per today's RNS Miton have been buying heavily again - they now own 11.73m shares here, or over 17%, so a big vote of confidence in an £11m m/cap company.

https://www.investegate.co.uk/enteq-upstream-plc--ntq-/rns/holding-s--in-company/202102251144033729Q/

Liberum have this morning initiated coverage on MGP with a huge 66 page report, saying Buy with a 200p target.....

There's a new 7 minute interview with a Zeus Capital Research analyst about SCE. He states that SCE can achieve between 25%-30% net margins, and at capacity 100,000 discs per year/£75m revenues he forecasts around £22m net profit per annum:

Https://www.***************************/surface-transforms-about-to-embark-on-an-exciting-phase-of-investment-and-growth-analyst-interview/412963297

Just to add, today's RNS shows imo the probity and trustworthiness of SCE's management. Not many - if any - RNS's go into such detail as to the thought process behind awarding share options, particularly when the options involved are really immaterial in overall terms.

New article from Atik Cameras about their role in COVID-19 PCR testing(not posted before):

Https://www.atik-cameras.com/news/pcr-solutions-sdi/

"Atik’s solutions for PCR help to provide positive outlook for SDI Group

Both prior to and throughout the COVID-19 pandemic, Atik Cameras has provided imaging solutions for real time PCR DNA amplifiers.

Of course, this has been a major source of pride for Atik from a humanitarian perspective. It is also the case that this has provided a positive contribution to Atik’s parent company, the SDI Group plc.

In part due to Atik and its imaging solutions for PCR, the SDI Group, which is listed on the LSE Alternative Investment Market (AIM) and focuses on the design and manufacture of scientific and technology products for use in digital imaging and sensing and control applications, is expecting to exceed its initial expectations for its financial year ending 30 April 2021.

This news has prompted Ken Ford, the Chairman of SDI to comment, “This is a significant endorsement of the Atik Camera design and production capability, recognising its expertise in imaging solutions for life sciences.”

Atik are delighted to continue to provide solutions for PCR, with our bespoke VS825 now being used in thousands of settings worldwide. The VS825 is a modified camera that showcases Atik’s flexible design philosophy and the ability to transfer expertise across domains to produce high quality, cost-effective customised solutions.

Furthermore, the ACIS series is also very well suited for use in PCR applications, featuring a selection of Sony CMOS sensors with fully customisable hardware and software options. The cameras in this series can be applied in a variety of different manners and to a wide range of projects.

Of course, PCR is simply one of the many applications that Atik Cameras can support, you can see more examples of the supported applications here. Additionally, you can view the recent webinar on imaging solutions in Life Sciences below."